Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2021-002789-42-AT
EUCTR2021-002789-42-AT
Active, not recruiting
Phase 1

Analysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study)

Medizinische Universität Innsbruck0 sites1,000 target enrollmentJuly 7, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAnalysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study)Therapeutic area: Body processes [G] - Immune system processes [G12]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Analysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study)
Sponsor
Medizinische Universität Innsbruck
Enrollment
1000
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 7, 2021
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Age (\= 18 years)
  • •2\. Decision\-making male and female Subjects
  • •3\. Has there been influenza, or SARS\-CoV\-2, or Pneumococcal vaccination (collective 1 \+ 2\) or already fixed vaccination date with an influenza, or
  • •SARS\-CoV\-2, or pneumococcal vaccination (Collective 1\)
  • •4\. Written, signed and dated Declaration of consent to participate in the clinical examination after prior written and oral explanation
  • •5\. Only applicable to subjects in collective 1: negative urine / serum pregnancy test Women of childbearing age
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 800

Exclusion Criteria

  • •Exclusion criteria
  • •1\. The subject is a presence or Training service provider
  • •2\. Parallel vaccination with a second vaccine within ± 14 days
  • •3\. Participation in an interventional study in the active phase
  • •4\. Only applicable to subjects in collective 1: Breastfeeding period

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Kinetics of immune responses and characteristics of antigen-specific B cells after Bordetella pertussis vaccinatioPertussisWhooping cough10004018
NL-OMON52999eids Universitair Medisch Centrum20
Completed
Not Applicable
Analysis of immune response behavior and agents by vaccination with new coronavirus infections in patients with hematopoietic malignancies
JPRN-UMIN000044850Hamamatsu University School of Medicine65
Recruiting
Phase 4
Evaluation of vaccine response to 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine in patients living with HIV/AIDS
RBR-3wshg2mHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Completed
Not Applicable
Characterization of the immune response in patients with urothelial cell carcinoma of the bladder and during the BCG immunotherapy of bladder cancerC67Malignant neoplasm of bladder
DRKS00003700Chirurgische Universitätsklinik, Abteilung für Urologie410
Completed
Not Applicable
RSV Challenge in Healthy AdultsRespiratory Infections, AcuteRespiratory Syncytial Virus
NCT00100373National Institute of Allergy and Infectious Diseases (NIAID)13